Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia in Remission With Detectable Measurable Residual Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission
Blood 2023 Oct 25;[EPub Ahead of Print], EJ Jabbour, FG Haddad, NJ Short, J Senapati, N Jain, K Sasaki, JL Jorgensen, SA Wang, Y Alvarado, X Wang, CD DiNardo, L Masarova, TM Kadia, R Garris, F Ravandi, HM KantarjianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.